Haberl I - Search Results

1

Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes.

Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Drach J, et al. Among authors: haberl i. Blood. 1996 Sep 1;88(5):1747-54. Blood. 1996. PMID: 8781431 Free article.

2

P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.

Haberl I, Swatonek H, Schaufler K, Ulsperger E, Wenzl E, Theyer G, Hamilton G, Thalhammer T. Haberl I, et al. Int J Oncol. 1998 May;12(5):1137-42. doi: 10.3892/ijo.12.5.1137. Int J Oncol. 1998. PMID: 9538140

3

Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract.

Hejna M, Hamilton G, Brodowicz T, Haberl I, Fiebiger WC, Scheithauer W, Virgolini I, Köstler WJ, Oberhuber G, Raderer M. Hejna M, et al. Among authors: haberl i. Anticancer Res. 2001 Mar-Apr;21(2A):1183-7. Anticancer Res. 2001. PMID: 11396161

4

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.

Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek GV, Vorbeck F, Hejna MH, Virgolini I, Scheithauer W. Raderer M, et al. Among authors: haberl i. Br J Cancer. 1999 Feb;79(3-4):535-7. doi: 10.1038/sj.bjc.6690084. Br J Cancer. 1999. PMID: 10027326 Free PMC article. Clinical Trial.

5

Nonsurgical management of malignant thymoma.

Hejna M, Haberl I, Raderer M. Hejna M, et al. Among authors: haberl i. Cancer. 1999 May 1;85(9):1871-84. Cancer. 1999. PMID: 10223225 Review.

6

Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3.

Platzer P, Herzog W, Thalhammer T, Hamilton G, Haberl I, Jäger W. Platzer P, et al. Among authors: haberl i. Anticancer Res. 1998 Jul-Aug;18(4A):2737-41. Anticancer Res. 1998. PMID: 9703938

7

In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.

Gabor F, Wollmann K, Theyer G, Haberl I, Hamilton G. Gabor F, et al. Among authors: haberl i. Anticancer Res. 1994 Sep-Oct;14(5A):1943-50. Anticancer Res. 1994. PMID: 7847832

8

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.

Theyer G, Holub S, Dürer A, Andert S, Haberl I, Theyer U, Hamilton G. Theyer G, et al. Among authors: haberl i. Br J Cancer. 1997;75(10):1515-8. doi: 10.1038/bjc.1997.259. Br J Cancer. 1997. PMID: 9166947 Free PMC article. Clinical Trial.

9

In vitro antitumor activity of MIC2 protein-doxorubicin conjugates.

Gabor F, Haberl I, Wirth M, Richter K, Theyer G, Baumgartner G, Wenzl E, Hamilton G. Gabor F, et al. Among authors: haberl i. Int J Oncol. 1996 Sep;9(3):527-31. doi: 10.3892/ijo.9.3.527. Int J Oncol. 1996. PMID: 21541546

10

Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.

Theyer G, Dürer A, Theyer U, Haberl I, Ulsperger E, Baumgartner G, Hamilton G. Theyer G, et al. Among authors: haberl i. Prostate. 1999 Oct 1;41(2):71-7. doi: 10.1002/(sici)1097-0045(19991001)41:2<71::aid-pros1>3.0.co;2-z. Prostate. 1999. PMID: 10477903

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters